The IMPAACT4TB Consortium has created a childfriendly version of rifapentine, a medication used in TB prevention and treatment. This development is crucial as over 2.25 million children need TB prevention treatment, and rifapentine was previously deemed unsuitable for children under 12. The shortterm treatment is affordable, costing between $6.53 to $15.80, and is expected to substantially reduce the number of children falling ill with TB, potentially saving thousands of lives. This medication marks a significant milestone in TB prevention, providing hope for lowtomiddleincome nations struggling with the disease.
